Your browser doesn't support javascript.
loading
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito, Tetsuhide; Okusaka, Takuji; Nishida, Toshirou; Yamao, Kenji; Igarashi, Hisato; Morizane, Chigusa; Kondo, Shunsuke; Mizuno, Nobumasa; Hara, Kazuo; Sawaki, Akira; Hashigaki, Satoshi; Kimura, Nobuyuki; Murakami, Mami; Ohki, Emiko; Chao, Richard C; Imamura, Masayuki.
Afiliação
  • Ito T; Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan. itopapa@intmed3.med.kyushu-u.ac.jp.
  • Okusaka T; Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
  • Nishida T; Department of Surgery, Osaka Police Hospital, Osaka, Japan.
  • Yamao K; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Igarashi H; Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, Japan.
  • Morizane C; Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
  • Kondo S; Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
  • Mizuno N; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Hara K; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Sawaki A; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Hashigaki S; Nagoya Daini Red Cross Hospital, Nagoya, Japan.
  • Kimura N; Pfizer Japan Inc., Tokyo, Japan.
  • Murakami M; Pfizer Japan Inc., Tokyo, Japan.
  • Ohki E; Pfizer Japan Inc., Tokyo, Japan.
  • Chao RC; Drug Delivery and Formulation Group, Medicinal Chemistry Platform, Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Imamura M; Pfizer Japan Inc., Tokyo, Japan.
Invest New Drugs ; 37(3): 591, 2019 Jun.
Article em En | MEDLINE | ID: mdl-30903344
In the original publication of this article, the license subtype should be CC BY and not CC BY-NC.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Invest New Drugs Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão